Skip to content
Buy This GLP
← Research
Evidence

Semaglutide 2.4 mg Persistence and Questionnaire Engagement at 48 Weeks

In one French program, 79.5% of people completing an optional assessment remained on semaglutide at 48 weeks, compared with 59.5% of nonusers.

Editorial profile: Carla MedinaBuy This GLP Editorial Team8 min read
Still on semaglutide at 48 weeks, by an optional questionnaireanswered before treatment began — nobody was assigned to answer itnever used it59.5%partly used it71.9%completed it79.5%Observed association in a single-center cohort.

Studies of how long people stay on a GLP-1 reflect different care settings. The study of weight outcomes at a UK online clinic uses recorded follow-up weights, while this study measured persistence through active prescriptions. The French study followed 191 adults with severe obesity in a structured early-access program at one French center [1]. The program supplied semaglutide at no cost to patients.

Who was still on treatment at 48 weeks

At week 48, 97 of 122 people who completed the optional baseline assessment remained on treatment (79.5%). The figure was 23 of 32 partial users (71.9%) and 22 of 37 nonusers (59.5%) [1].

Each step up in engagement was associated with higher adjusted odds of continuing treatment. The estimated odds ratio was 1.62 (95% CI 1.05 to 2.50). Participants chose how much of the assessment to complete. The study defined persistence as an active prescription at the 48-week visit.

What a questionnaire can tell us

Research on why people stop taking GLP-1 drugs describes barriers in other settings. Here, time, language, internet access or other differences could affect both completion and persistence.

The association cannot show what would happen if a clinic assigned the questionnaire. Persistence percentages from this program may differ from those in other settings.

Frequently asked

Did the questionnaire help people stay on treatment?
People who completed it stayed on treatment more often. The study did not randomly assign engagement, so it cannot determine whether completion helped.

Sources

  1. [1] Tournayre S, et al. (2026). Digital Engagement and Predictors of Semaglutide Persistence and Weight Loss in Severe Obesity: 48-Week Observational Study Journal of Medical Internet Research. PMID 42684246

Where to get it

Price the injectable sellers

The desk lists every seller that publishes an injectable figure, with the advertised price struck against the one a buyer is billed.

Open the price desk →

More in Evidence